Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
McKinsey
AstraZeneca
Covington
Daiichi Sankyo
Novartis
US Army
US Department of Justice
Johnson and Johnson
Cerilliant

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,895,557 protect, and when does it expire?


Patent ► Subscribe protects YONDELIS and is included in one NDA.

This patent has thirty-nine patent family members in thirty-five countries.

Summary for Patent: ► Subscribe

Title:Pharmaceutical formulations of ecteinascidin compounds
Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
Inventor(s): Beijnen; Jacob Hendrik (Amsterdam, NL), Nuijen; Bastiaan (Amsterdam, NL), Salve; Pilar Calvo (Madrid, ES), Barreira; Maria Tobio (Madrid, ES)
Assignee: Pharma Mar, S.A., Sociedad Unipersonal (Madrid, ES)
Application Number:11/261,876
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Prods
YONDELIS
trabectedin
POWDER;IV (INFUSION)207953-001Oct 23, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2007119724► Subscribe
Serbia50510► Subscribe
Portugal1658848► Subscribe
Peru09252006► Subscribe
Peru00892010► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Johnson and Johnson
US Department of Justice
Baxter
Cantor Fitzgerald
Deloitte
Colorcon
Fish and Richardson
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot